Baricitinib Enhances RA Patients’ Outcomes in Phase 3 Trial
News
Patients with rheumatoid arthritis (RA) and inadequate responses to biological disease-modifying antirheumatic drugs (bDMARDs) show a positive response to treatment with baricitinib (LY3009104), with the therapy improving several patient-reported outcomes, ... Read more